The global varicose vein treatment market is expected to reach USD 475 million by 2024, according to a new report by Grand View Research, Inc. The increasing technological advancements coupled with the increased availability of the advanced varicose vein treatment devices and shift towards less-invasive procedures are the contributing factors for the growth of the market.
The huge burden of vascular diseases in Europe and North America and the increasing patient compliance and reliability, growth in healthcare expenditure, and the rapid growth in geriatric population is majorly driving the varicose vein procedure market.
The upward trend in lifestyle disorders, such as increasing obesity, sleep disorders, blood pressure levels, hormonal changes, genetic disorders and pregnancy are the few major factors contributing to the peripheral vascular diseases. Untreated venous insufficiency, such as varicose vein and venous ulcers cause progressive syndromes including chronic veinous insufficiency. In 2015, according to FutSci, chronic veinous insufficiency is widespread and is a socially isolating condition caused in adults. It is the most common disease in the world and is estimated to affect 5% of the population in the Western countries.
To request a sample copy or view summary of this report, click the link below:
Further key findings from the report suggest:
In 2015, the sclerotherapy segment was identified as the most profitable procedure owing to the benefits, such as the requirement of minimal incision and reduced scarring, related to the procedure. Moreover,the following advantages: increased penetration, cost and time efficiency, reduced risk of collateral damage to surrounding tissues, fewer post-operative complications, and painless procedure are the main contributors for the growth of this segment.
The endovenous ablation segment is expected to be the fastest growing segment due to the benefits of short treatment time and improved blood circulation after the procedure. The ClosureFast technique in the endovenous ablation treatment segmenthas gained momentum due to the minimized side effects, potential cost-saving ability, and better patient outcomes.
In 2015, the endovenous chemoablation or chemical sclerosis segment was the most widely used medical procedure among the ablation procedures. Sclerotherapy, intense-pulsed-light therapy, laser ablation, radiofrequency, and ambulatory phlebectomy are the modern techniques that are usedmore oftendue to their less invasive nature.
In 2016, North America held the largest market share due to the increasing incidence rate of varicose and spider vein in the population, favourable reimbursement policies, increased healthcare awareness, government spending, and the rising aesthetic awareness in the region
As of 2016, Europe is characterized by a shift towards less-invasive procedures in treating large varicose veins. It is expected to witness a high growth rate over the forecast period due to the favorable government initiatives and advanced treatment procedures.
The Asia Pacific is expected to register the fastest growth due to factors, such as the improving healthcare infrastructure, the increase in patient awareness level regarding the benefits of early treatment of the varicose veins, and the rising disposable income
Some key players of the market include Quanta Systems S.p.A, Vascular Solutions, Inc., Eufoton S.R.L, Energist Group, Medtronic plc, Dornier MedTech GmbH, Lumenis Ltd., Syneron Medical Ltd., Biolitec AG, and AngioDynamics, Inc.
AngioDynamics, Inc. and MerzPharma GmbH & Co. KGaAin North America established a multi-year relationship to market Asclera for patients with peripheral vascular diseases.In the U.S,.MerzPharma GmbH & Co. KGaAserves as the exclusive distributor of the Asclera Injection. Asclera is approved for the treatment of spider and reticular veins, which showed good improvement in 95% of the patients treated with asclera.
In 2016, Medtronic plc acquired Italian hemodialysis player Bellco, Inc.This acquisition is projected to enable the medical device giant to gain market position in newly formed renal care solution business.
In 2015, Medtronic plc acquired Covidien plc with the objective to move into the additional therapeutic areas, such as chronic venous insufficiency. Covidien plc markets the Venefit procedure that uses radiofrequency energy and minimally invasive radiofrequency ablation to treat the disease.
Grand View Research has segmented the global varicose vein treatment market on the basis of procedures, devices,and regions:
Varicose Vein Treatment Outlook ByType (Revenue, USD Million, 2013 - 2024)
Varicose Vein Treatment Regional Outlook (Revenue, USD Million, 2013 - 2024)
Rest of Europe
Rest of Asia Pacific
Rest of Latin America
Rest of MEA
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."